first recurrence
Showing 1 - 25 of >10,000
Glioblastoma Trial in Münster (Gliolan, Radiodynamic therapy)
Recruiting
- Glioblastoma
- Gliolan
- Radiodynamic therapy
-
Münster, GermanyUniversity Hospital Münster, Klinik für Neurochirurgie
Nov 16, 2022
Glioma, Recurrent Glioma Trial in Shanghai (Hypofractionated Stereotactic Radiotherapy, Bevacizumab)
Active, not recruiting
- Glioma
- Recurrent Glioma
- Hypofractionated Stereotactic Radiotherapy
- Bevacizumab
-
Shanghai, Shanghai, ChinaCyberKnife Center, Department of Neurosurgery, Huashan Hospital
Nov 3, 2022
Clostridioides Difficile Infection Trial in Lausanne (oral capsulized Fecal Microbiota Transplantation, Vancomycin or
Recruiting
- Clostridioides Difficile Infection
- oral capsulized Fecal Microbiota Transplantation
- Vancomycin or Fidaxomicin
-
Lausanne, Vaud, SwitzerlandCHUV
Aug 16, 2022
Brain Metastases Trial (Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy)
Not yet recruiting
- Brain Metastases
- Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)
- Stereotactic Radiation Therapy
- (no location specified)
Jun 2, 2023
Arrhythmic Recurrence in Paroxysmal AF Undergoing First Ablation
Recruiting
- Atrial Fibrillation Paroxysmal
- Standard of care
- Data collection
-
Ancona, Italy
- +1 more
Oct 11, 2023
Seizure Recurrence After Unprovoked First Seizure
Not yet recruiting
- Single Seizure
- Epilepsy
-
Halifax, Nova Scotia, Canada
- +1 more
Feb 14, 2023
Ovarian Cancer Trial in Guangzhou (Pamiparib/Tamoxifen)
Not yet recruiting
- Ovarian Cancer
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Centre
Dec 30, 2022
Postoperative Recurrence in Biliary Tract Cancers:A Multicenter
Recruiting
- Biliary Tract Cancer
- No intervention
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with NanJing Medical University
Feb 15, 2023
Melanoma Trial (Blood samples, Skin biopsy)
Not yet recruiting
- Melanoma
- Blood samples
- Skin biopsy
- (no location specified)
Oct 3, 2022
Hepatocellular Carcinoma Trial in Hangzhou (Anlotinib Hydrochloride)
Terminated
- Hepatocellular Carcinoma
- Anlotinib Hydrochloride
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
Aug 25, 2022
Hepatocellular Carcinoma, TACE, Anlotinib Trial in Lanzhou, Xi'an (Anlotinib Hydrochloride, TACE)
Active, not recruiting
- Hepatocellular Carcinoma
- +2 more
- Anlotinib Hydrochloride
- TACE
-
Lanzhou, Gansu, China
- +3 more
Jan 12, 2023
Psychotic Episode Trial in France (Case management)
Recruiting
- Psychotic Episode
- Case management
-
Clermont-Ferrand, France
- +6 more
Jan 2, 2023
Advanced Cancer, Metastatic Cancer Trial in Shanghai (biological, device, drug)
Recruiting
- Advanced Cancer
- Metastatic Cancer
- Autologous Adoptive immune cells
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Pudong Medical Center
Jun 24, 2022
Prostate Cancer, PET/CT Trial in Hefei ([68Ga]Ga-PSMA-D5, [68Ga]Ga-PSMA-11)
Recruiting
- Prostate Cancer
- PET/CT
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of China University of Science and
Jul 19, 2023
Mean Gestational Sac Diameter and Crown-rump Length asMarker of
Completed
- Recurrent Spontaneous Abortion
- ultrasonic testing
-
Xiamen, Fujian, ChinaThe First Affiliated Hospital of Xiamen University
Oct 7, 2023
Prostate Cancer, Biochemical Recurrence, High Risk Trial in Nanjing, Nantong (Apalutamide 60mg Tab, Androgen deprivation
Not yet recruiting
- Prostate Cancer
- +2 more
- Apalutamide 60mg Tab
- Androgen deprivation therapy(ADT)
-
Nanjing, Jiangsu, China
- +2 more
Mar 17, 2023
Colorectal Cancer Trial in China (Huaier granule)
Not yet recruiting
- Colorectal Cancer
- Huaier granule
-
Harbin, Heilongjiang, China
- +8 more
Oct 15, 2023
Colorectal Cancer Survivor, Rehabilitation, Quality of Life Trial (multidimensional rehabilitation)
Not yet recruiting
- Colorectal Cancer Survivor
- +2 more
- multidimensional rehabilitation
- (no location specified)
Jul 21, 2023
MRD Application in Colorectal Cancer Patients
Recruiting
- Colorectal Cancer
- +2 more
-
Jinan, Shandong, ChinaJinan central hospital affiliated to Shandong First Medical Univ
Sep 1, 2023
Hepatocellular Carcinoma Trial in Hefei (Tislelizumab + Sitravatinib)
Recruiting
- Hepatocellular Carcinoma
- Tislelizumab + Sitravatinib
-
Hefei, Anhui, ChinaAnhui province hospital
Jul 27, 2022
Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism Trial in Netherlands (Randomised treatment advice (discontinue vs
Recruiting
- Venous Thromboembolism
- +3 more
- Randomised treatment advice (discontinue vs continue after 3 months)
- +4 more
-
Leiden, South-Holland, Netherlands
- +16 more
Oct 17, 2023
Graves Disease, Relapse, Treatment Trial in Nanjing (Methimazole)
Recruiting
- Graves Disease
- +3 more
-
Nanjing, Chinathe First Affiliated Hospital of Nanjing Medical University
Jul 21, 2022
Prostate Cancer Trial in Fuzhou (A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide)
Not yet recruiting
- Prostate Cancer
- A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide
-
Fuzhou, Fujian, ChinaDepartment of Nuclear Medicine, First Affiliated Hospital of Fuj
Aug 23, 2022
Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))
Completed
- Hepatocellular Carcinoma
- TCR-T
- No intervention and TCR-T (at crossover)
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital, Sun-Yat Sen University
Jun 27, 2022